Abstract
Prior to enactment of the final investigational new drug application (IND) safety reporting rule, an attempt was made to document the effort expended at investigative sites in processing IND safety reports from sponsors and to assess the effect of these expedited reports on trial conduct. Investigators were asked to (1) prospectively document time to process IND safety reports and (2) retrospectively review safety reports from a previous 3-month period, documenting resultant actions. In this limited sample, sites spent a median of 0.25 hours per report at a median cost of US$22. Few expedited safety reports were retrospectively said to have changed study conduct or informed consent. However, a low response rate and the concentration of clinical sites in a single therapeutic area preclude generalizing these results. The authors discuss the challenges in gaining investigators’ cooperation to evaluate the impact of regulatory requirements. Better methods to facilitate this type of research will enrich the scientific basis of future clinical trial regulation and guidance.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Fed Regist. 2010;75(188):59935–59963. To be codified at 21 CFR §312 and §320.
Duley L, Antman K, Arena J, et al. Specific barriers to the conduct of randomized trials. Clin Trials. 2008;5;40–48.
Clinical Trial Transformation Initiative. http://www.ctti-clinicaltrials.org. Accessed November 17, 2013.
European Commission. Detailed guidance on the collection, verification, and presentation of adverse reaction reports arising from clinical trials on medicinal products for human use. http://ec.europa.eu/health/files/eudralex/vol-10/2011_c172_01/2011_c172_01_en.pdf. Published April 2006. Updated June 2011. Accessed January 22, 2013.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban vs warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for industry and investigators: safety reporting requirements for INDs (investigational new drug applications) and BA/BE (bioavailability/bioequivalence) studies. http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm121568.htm. Published December 2012. Accessed January 22, 2013.
Archdeacon P, Grandinetti C, Vega JM, Balderson D, Kramer JM. Optimizing expedited safety reporting for drugs and biologics subject to an investigational new drug application [published online November 7, 2013]. Therapeutic Innovation & Regulatory Science.
Archdeacon P. Summary of results on perspectives of LSTs survey. http://www.ctti-clinicaltrials.org/files/documents/LSTmeeting-PArchdeacon_LSTDay1.pdf. Accessed October 25, 2013.
Califf RM, Platt R. Embedding cardiovascular research into practice. JAMA. 2013;310:2037–2038.
Kramer JM, Smith PB, Califf RM. Impediments to clinical research in the United States. Clin Pharmacol Ther. 2012;91:535–541.
European Science Foundation. Forward look: investigator-driven clinical trials. http://www.esf.org/fileadmin/Public_documents/Publications/IDCT.pdf. Published 2009. Accessed October 25, 2013.
Califf RM. Clinical research sites: the underappreciated component of the clinical research system. JAMA. 2009;302:2025–2027.
Author information
Authors and Affiliations
Corresponding author
Additional information
Dr. Vock is currently affiliated with the University of Minnesota, Minneapolis, MN, USA
Dr. Greenberg is currently affiliated with Janssen Pharmaceuticals, Titusville, NJ, USA
Dr. Szczech is currently affiliated with FibroGen Inc, San Francisco, CA, USA
Dr. Salgo has retired from Genentech
Dr. Gagnon is currently affiliated with Idis Ltd, Princeton, NJ, USA and with West Chester University of Pennsylvania, West Chester, PA, USA
Authors’ Note
The views expressed herein represent those of the authors and do not necessarily represent the views or practices of the authors’ employers or any other party.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kramer, J.M., Vock, D., Greenberg, H.E. et al. Investigators’ Experience With Expedited Safety Reports Prior to the FDA’s Final IND Safety Reporting Rule. Ther Innov Regul Sci 48, 413–419 (2014). https://doi.org/10.1177/2168479013520160
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1177/2168479013520160